SEC Form 4/A · accession 0001209191-17-033946
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Neil Bodick
Officer — Chief Medical Officer
Period of report
Apr 17, 2017
Accepted (ET)
May 19, 2017 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 17, 2017 | M | 5,000 | $2.5203 | A | 64,937 | D | |
| Common StockF3 | Apr 17, 2017 | S | 4,800 | $28.20 | D | 60,137 | D | |
| Common StockF4 | Apr 17, 2017 | S | 200 | $28.86 | D | 59,937 | D | |
| Common StockF5 | holding | — | — | — | 388,683 | I | By Versant Development Fund III, LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F6 | $2.5203 | Apr 17, 2017 | M | 5,000 | D | — | Aug 28, 2022 | Common Stock | 5,000 | 44,302 | D |
Explanation of responses
- F1This Form 4 is being amended to include the option exercise that occurred in connection with the reported sale and to correct the number of securities beneficially owned following the reported transaction.
- F2Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted June 23, 2016.
- F3The weighted average sale price for the transaction reported was $28.20, and the range of prices were between $27.77 and $28.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F4The weighted average sale price for the transaction reported was $28.86, and the range of prices were between $28.83 and $28.89. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F5Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
- F6The stock option is fully vested and exercisable.